

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001585160
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Regeneron Pharmaceuticals, Inc.
SEC File Number 000-19034
Address of Issuer 777 Old Saw Mill River Road
Tarrytown
NEW YORK
10591
Phone 914-847-7000
Name of Person for Whose Account the Securities are To Be Sold Robert Landry

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Former CFO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	2500	2375000	107943750	02/07/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

	Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Common Stock	02/02/2024 Stock Option Exercise	Company	<input type="checkbox"/>	119	02/02/2024 Stock
Common Stock	01/31/2024 Stock Option Exercise	Company	<input type="checkbox"/>	118	01/31/2024 Stock
Common Stock	01/24/2024 Stock Option Exercise	Company	<input type="checkbox"/>	148	01/24/2024 Stock
Common Stock	01/23/2024 Stock Option Exercise	Company	<input type="checkbox"/>	324	01/23/2024 Stock
Common Stock	01/17/2024 Stock Option Exercise	Company	<input type="checkbox"/>	146	01/17/2024 Stock
Common Stock	01/12/2024 Stock Option Exercise	Company	<input type="checkbox"/>	232	01/12/2024 Stock
Common Stock	01/04/2024 Stock Option Exercise	Company	<input type="checkbox"/>	158	01/04/2024 Stock
Common Stock	01/03/2024 Stock Option Exercise	Company	<input type="checkbox"/>	412	01/03/2024 Stock
Common Stock	01/02/2024 Stock Option Exercise	Company	<input type="checkbox"/>	229	01/02/2024 Stock
Common Stock	12/28/2023 Stock Option Exercise	Company	<input type="checkbox"/>	238	12/28/2023 Stock
Common Stock	12/27/2023 Stock Option Exercise	Company	<input type="checkbox"/>	208	12/27/2023 Stock
Common Stock	12/13/2023 Stock Option Exercise	Company	<input type="checkbox"/>	277	12/13/2023 Stock
Common Stock	12/12/2023 Restricted Stock Award	Company	<input type="checkbox"/>	6119	12/12/2023 Stock

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice 02/07/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ UBS Financial Services Inc, as attorney-in-fact for Robert Landry

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)